FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 北京鷹瞳科技發展股份有限公司(「本公司」) (於中華人民共和國註冊成立的股份有限责任公司) 呈交日期： 2025年12月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | ...

Group 1 - The "Qihang·2025 Financial Summit" was successfully held on December 26 in Beijing, focusing on the theme "New Starting Point, New Momentum, New Journey," gathering hundreds of leaders and guests from regulatory bodies, industry associations, financial institutions, listed companies, and media [1] - The 14th "Jinzhi Award" results were announced, with Airdoc winning the title of "Outstanding Frontier Technology Enterprise," highlighting its recognition in the field of innovative technology [1][3] - The "Jinzhi Award" aims to establish benchmarks for high-quality development, guiding listed companies to focus on their core businesses, continue innovation, and fulfill social responsibilities, thereby promoting capital concentration towards quality enterprises [3] Group 2 - Airdoc, founded in 2015, is dedicated to providing comprehensive AI solutions for chronic disease early screening and management, myopia prevention, stress monitoring, and amblyopia treatment, positioning itself as a leader in the global retinal imaging AI field [4] - Airdoc became the first company in China to obtain NMPA registration for Class III AI-assisted diagnostic medical devices for retinal imaging, marking a significant achievement in the medical AI sector [4] - As of now, Airdoc's AI retinal imaging products have provided disease auxiliary diagnosis and health risk assessment for 30 million people, showcasing its impact in the healthcare industry [4]

Core Insights - The 2025 edition of the "Health Blue Book" based on retinal AI assessment was officially released, marking the seventh consecutive year of publication by iKang Group and Eagle Eye Technology [1][2] - The cumulative sample size has surpassed 6 million, with over 1 million individuals undergoing retinal AI assessments multiple times, providing valuable data for public health research [1][2] Group 1: Company Initiatives - iKang Group initiated the retinal AI health assessment project in 2018, starting with over 200,000 users in the first year and adding approximately 1 million users annually [2] - The data for the "Blue Book" is sourced from 6,481,674 examination records collected between July 2018 and June 2025 from individuals participating in the retinal AI health assessment project [2] - iKang Group has launched the iKangAI+ plan to maximize medical accessibility, integrating AI products into traditional health examinations, resulting in the creation of the "iKang AI Matrix" with over 10 specialized health screening products [2] Group 2: Technological Development - The retinal AI technology is aimed at accurately assessing eye health and identifying disease risks, contributing significantly to comprehensive health analysis [2] - All health examination centers under iKang Group are equipped with Eagle Eye Technology's retinal AI health assessment products to facilitate early detection of eye abnormalities and chronic disease risks [2]

Group 1 - The company Eagle Vision Technology-B (02251) announced a share buyback plan, spending approximately HKD 68.1 million to repurchase 5,700 shares [1]

Group 1 - The company Eagle Vision Technology-B (02251) announced a share buyback plan, spending approximately HKD 68.1 million to repurchase 5,700 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年12月22日 | | 102,517,613 | | 1,050,400 | | 103,568,013 | | 1). 購回股份 (股份被持作庫存股份) | | | -5,700 ...

Group 1 - The company, Eagle Vision Technology-B (02251), announced a share buyback plan, spending approximately HKD 170,700 to repurchase 14,500 shares [1]

智通财经APP讯，鹰瞳科技-B(02251)公布，2025年12月22日耗资约17.07万港元回购1.45万股股份。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 北京鷹瞳科技發展股份有限公司(「本公司」) (於中華人民共和國註冊成立的股份有限责任公司) 呈交日期： 2025年12月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | ...

Group 1 - The company Eagle Vision Technology-B (02251) announced a share buyback plan, spending approximately HKD 484,100 to repurchase 40,900 shares [1]